^
BIOMARKER:

KRAS G12R

i
Other names: KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
Entrez ID:
Related biomarkers:
KRAS G12R
Colon Cancer
cetuximab
Resistant: B - Late Trials
KRAS G12R
CRC
panitumumab
Resistant: B - Late Trials
KRAS G12R
Pancreatic Adenocarcinoma
selumetinib
Sensitive: C3 – Early Trials
KRAS G12R
Pancreatic Cancer
cobimetinib
Sensitive: C3 – Early Trials
KRAS G12R
HCC
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
KRAS G12R
NSCLC
erlotinib
Resistant: C3 – Early Trials
KRAS G12R
Gastric Cancer
imatinib
Resistant: C4 – Case Studies
KRAS G12R
CRC
sunitinib
Resistant: D – Preclinical
KRAS G12R
Thyroid Gland Carcinoma
trametinib + dasatinib
Sensitive: D – Preclinical
KRAS G12R
Thyroid Gland Carcinoma
trametinib
Sensitive: D – Preclinical
KRAS G12R
Thyroid Gland Carcinoma
dasatinib + SCH772984
Sensitive: D – Preclinical
KRAS G12R
Thyroid Gland Medullary Carcinoma
RTB101 + RAF265
Sensitive: D – Preclinical
KRAS G12R
Thyroid Gland Carcinoma
dasatinib + selumetinib
Sensitive: D – Preclinical
KRAS G12R
Thyroid Gland Carcinoma
dasatinib
Sensitive: D – Preclinical
KRAS G12R
Thyroid Gland Anaplastic Carcinoma
GSKJ4
Sensitive: D – Preclinical